Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2021, Vol. 48 Issue (3): 601-606    DOI: 10.31083/j.ceog.2021.03.2437
Original Research Previous articles | Next articles
Outcomes and dose—volume parameters for computed tomography-based brachytherapy planning for vaginal recurrence of uterine cancer primarily treated with surgery
Keiko Nemoto Murofushi1, 2, *(), Reiko Tanaka1, Ayako Ohkawa1, Haruko Numajiri1, Toshiyuki Okumura1, Hideyuki Sakurai1
1Faculty of Medicine, Department of Radiation Oncology & Proton Medical Research Center, University of Tsukuba, Tsukuba, 305-8576 Ibaraki, Japan
2Division of Radiation Oncology, Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, 113-8677 Tokyo, Japan
Download:  PDF(784KB)  ( 45 ) Full text   ( 2 )
Export:  BibTeX | EndNote (RIS)      
Background: This study aimed to evaluate the clinical outcomes and dose-volume parameters of computed tomography CT-based brachytherapy for the vaginal recurrence of uterine cancer after hysterectomy. Methods: We evaluated 22 uterine cancer patients treated with CT-based brachytherapy for vaginal recurrence between December 2010 and August 2015. Interstitial brachytherapy (ISBT) was used when the vaginal tumor was thicker than 5 mm and/or located at extended extravaginal tissue, whereas intercavitary brachytherapy was performed if it was 5 mm or thinner. Results: Overall, 11 patients had cervical cancer, and 11 had endometrial cancer. The median pretreatment tumor size on magnetic resonance imaging was 17 mm (range, 0–45 mm). Four patients had vaginal recurrence recognized only in the gynecological examination. The primary location of recurrence was the vagina, with extravaginal extension observed in 9 patients. Seventeen patients (77%) received external beam radiotherapy and brachytherapy. ISBT was performed in 12 patients (55%). The median clinical target volume (CTV) D90 was 69.2 Gy (62.6–72.8 Gy). The median D2cc of the bladder, sigmoid, and rectum were 70.2 (63.8–77.6), 37.4 (30.0–43.6), and 52.8 Gy (38.6–63.5 Gy), respectively. Complete response was reached in all patients. The 5-year overall survival rate and local control rate (LC) were 84.8 and 95.5%, respectively. No patient experienced grade geq3 complications. Conclusions: CT-based brachytherapy has the potential to become an essential treatment for vaginal recurrences of uterine cancer after hysterectomy as it can achieve good LC without increasing the rate of late complications for selected patients with less recurrences.
Key words:  Vaginal recurrence      High-dose-rate brachytherapy      Intracavitary brachytherapy      Interstitial brachytherapy      Image-guided adaptive brachytherapy     
Submitted:  29 December 2020      Revised:  23 February 2021      Accepted:  29 March 2021      Published:  15 June 2021     
18xx0000000 h 0001/Medical Research and Development (AMED)
*Corresponding Author(s):  Keiko Nemoto Murofushi     E-mail:

Cite this article: 

Keiko Nemoto Murofushi, Reiko Tanaka, Ayako Ohkawa, Haruko Numajiri, Toshiyuki Okumura, Hideyuki Sakurai. Outcomes and dose—volume parameters for computed tomography-based brachytherapy planning for vaginal recurrence of uterine cancer primarily treated with surgery. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 601-606.

URL:     OR

No related articles found!
No Suggested Reading articles found!